Summary Death by Stem Cell: Developing New Cancer Therapies | The Scientist Magazine® www.the-scientist.com
3,304 words - html page - View html page
One Line
Khalid Shah has developed a twin stem cell system to specifically treat cancer at Brigham and Women's Hospital.
Slides
Slide Presentation (8 slides)
Key Points
- Khalid Shah is developing stem cell-based therapies to treat brain and lung cancers.
- Stem cells are being used as delivery vectors for cancer therapeutics, increasing their efficacy in targeting tumors.
- Shah's laboratory developed an allogeneic twin stem cell system to treat brain metastases and engineered mesenchymal stem cells to target lung tumors.
- Stem cell-based therapy transportation offers advantages such as sustained release of therapeutics and improved targeting of tumors.
- Shah emphasizes the importance of building infrastructure to support translational research in cancer therapy development.
Summaries
18 word summary
Khalid Shah at Brigham and Women's Hospital has created a twin stem cell system for targeted cancer treatment.
68 word summary
Khalid Shah, director of the Center for Stem Cell and Translational Immunotherapy at Brigham and Women's Hospital, has developed a system using twin stem cells to deliver cancer treatments directly to tumors, resulting in cancer cell death. Stem cells offer advantages over intravenous administration, allowing for sustained release and improved tumor targeting. Shah envisions a future where stem cell-based therapies are widely available and economical for patients worldwide.
141 word summary
Khalid Shah, director of the Center for Stem Cell and Translational Immunotherapy at Brigham and Women's Hospital, is researching stem cell-based therapies for brain and lung cancers. His lab has developed a system using twin stem cells to deliver cancer treatments directly to tumors, resulting in cancer cell death. Stem cells as a delivery method offer advantages over intravenous administration, allowing for sustained release of therapeutics and improved tumor targeting. Shah's interest in stem cells as a delivery method stemmed from his search for proteins that could specifically target and kill tumor cells without harming healthy cells. He emphasizes the importance of building infrastructure to support translational research in cancer therapy development. Shah envisions a future where stem cell-based therapies are more widely available and economical for patients worldwide, as cell therapies continue to evolve and become a viable treatment option.
419 word summary
Khalid Shah, director of the Center for Stem Cell and Translational Immunotherapy at Brigham and Women's Hospital, is working on stem cell-based therapies for brain and lung cancers. His research involves using stem cells to deliver cancer treatments directly to tumors, increasing their effectiveness. In a recent study, Shah's lab developed a system using twin stem cells to transport oncolytic viral particles and immunomodulators to treat brain metastases. They also engineered mesenchymal stem cells to target receptors in lung tumors, resulting in cancer cell death.
Using stem cells as a delivery method for cancer therapies offers advantages over direct intravenous administration. Many therapeutic proteins have short half-lives, requiring repeated administration. The blood-brain barrier also poses challenges for delivering treatments to brain tumors. By delivering stem cells directly to the tumor site, therapeutics can be released over time and tumors can be targeted more effectively. Shah's lab has pioneered the use of oncolytic virus-loaded stem cells, which protect viral particles and deliver them directly to tumors.
Shah's interest in using stem cells as a delivery method stemmed from his search for proteins that could specifically target and kill tumor cells without harming healthy cells. He became interested in genetically engineering stem cells to release therapeutics once they reached tumors. Stem cells have been found to migrate toward brain tumors, making them a promising vehicle for targeted drug delivery.
Shah emphasizes the importance of not only innovation but also building infrastructure to support translational research in cancer therapy development. While there is a focus on developing new technologies, it is crucial to establish a framework that allows these innovations to be effectively translated into clinical applications.
Looking ahead, Shah envisions a future where stem cell-based therapies are more widely available and economical for patients worldwide. He believes that as cell therapies continue to evolve, hospitals and healthcare centers will become better equipped to administer these treatments. The field of cell therapy has made significant advancements in the past decade, and the next 10 years hold promise for further advancements and widespread adoption of cell therapy as a viable treatment option.
In summary, Khalid Shah is developing stem cell-based therapies for brain and lung cancers. He aims to enhance the efficacy of cancer treatments by using stem cells as delivery vectors. Stem cell-based therapy offers advantages such as sustained release of therapeutics and improved tumor targeting. Shah emphasizes the need for infrastructure to support translational research and envisions a future where cell therapies are more readily available and affordable for patients worldwide.
495 word summary
Khalid Shah, the director of the Center for Stem Cell and Translational Immunotherapy at Brigham and Women's Hospital and a professor at Harvard Medical School, is developing stem cell-based therapies to treat brain and lung cancers. Shah's research focuses on using stem cells as delivery vectors for cancer therapeutics, increasing their efficacy in targeting tumors. In a recent study published in Science Translational Medicine, Shah's laboratory developed an allogeneic twin stem cell system that carries oncolytic viral particles and immunomodulators to treat brain metastases. Another study published in Stem Cells Translational Medicine engineered mesenchymal stem cells to secrete a bi-functional molecule targeting receptors in lung tumors, leading to cancer cell death.
Stem cell-based therapy transportation offers several advantages compared to direct intravenous therapy administration. Many therapeutic proteins or antibodies have short half-lives, requiring repeated administration. Additionally, the blood-brain barrier poses challenges for delivering therapeutics to brain tumors. Local delivery of stem cells to the tumor site bypasses these issues, allowing for sustained release of therapeutics and enhanced targeting of tumors. Shah's lab has pioneered the use of oncolytic virus-loaded stem cells, which protect viral particles as they travel through the body and deliver them directly to the tumor site, increasing the amount of virus delivered.
Shah's interest in using stem cells as a delivery method for cancer therapies stemmed from his investigation into proteins that could specifically target and kill tumor cells without harming healthy cells. He became intrigued by the idea of genetically engineering stem cells to release therapeutics once they homed in on tumors. Stem cells have been found to migrate toward tumors in the brain, making them a promising vehicle for targeted drug delivery.
In terms of cancer therapy development, Shah emphasizes the importance of not only innovation but also building infrastructure to support translational research. While there is a focus on developing innovative technologies, it is crucial to establish a framework to ensure that these innovations can be effectively translated into clinical applications.
Looking to the future, Shah envisions a bright future for stem cell-based therapies. He believes that as cell therapies continue to evolve, hospitals and healthcare centers worldwide will become better equipped to administer these treatments to patients more effortlessly and economically. The field of cell therapy has made significant advancements in the past decade, with treatments based on chimeric antigen receptor T cells, natural killer cells, and stem cells. The next 10 years hold promise for further advancements and widespread adoption of cell therapy as a viable treatment option.
In summary, Khalid Shah's research focuses on developing stem cell-based therapies for brain and lung cancers. By using stem cells as delivery vectors, Shah aims to enhance the efficacy of cancer therapeutics in targeting tumors. Stem cell-based therapy transportation offers advantages such as sustained release of therapeutics and improved targeting of tumors. Shah emphasizes the importance of building infrastructure to support translational research and envisions a future where cell therapies are more readily available and economical for patients worldwide.